The Patented Medicine Prices Review Board (PMPRB) is a Federal tribunal that monitors the price of patented drug products in Canada to ensure that prices are not excessive. Manufacturers are required to notify the PMPRB upon launch of a new patented drug product, and then provide sales reports to the PMPRB for the period on an ongoing basis.
The PMPRB had previously announced that it would replace the current semi-annual sales reporting with an annual report. However, because the PMPRB has now indicated that it will not move to an annual reporting requirement and this initiative has been removed from the government’s Forward Regulatory Plan, the previously established Regulations will continue to be enforced without change at this time.
For more information, click here.